{"id":4577,"date":"2021-08-20T06:00:00","date_gmt":"2021-08-20T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/"},"modified":"2021-08-20T06:00:00","modified_gmt":"2021-08-20T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-juni-2021","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>F\u00f6rsta kliniska studien startad och l\u00e5ngsiktig finansiering s\u00e4krad<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under andra kvartalet 2021<\/strong><\/p>\n<ul>\n<li>Nanexa startade sin f\u00f6rsta kliniska studie i slutet av april 2021. Det \u00e4r en fas I-studie i NEX-18-projektet som g\u00f6rs f\u00f6r att studera farmakokinetik, s\u00e4kerhet och tolerabilitet. F\u00f6rsta patienten behandlades i slutet av maj 2021.<\/li>\n<li>Applied Ventures investerade ytterligare 0,5 miljoner dollar genom nyttjande av teckningsoptioner som emitterats i samband med den riktade emissionen i Q1 2021. Nanexa tillf\u00f6rdes genom emissionen 4,3 miljoner kronor och antalet aktier och r\u00f6ster i bolaget \u00f6kade med 480 879 till 25 347 813 aktier och r\u00f6ster.<\/li>\n<li>Nanexa erh\u00f6ll i maj 2021 godk\u00e4nnande i Kina f\u00f6r sitt grundpatent, som omfattar tillverkningsmetoden, produkter som kommer ut av den, samt anv\u00e4ndning av PharmaShell\u00ae-belagda l\u00e4kemedel.<\/li>\n<li>Vid Nanexas \u00e5rsst\u00e4mma den 24 maj beslutades bl a att v\u00e4lja Eva Nilsag\u00e5rd och Birgit Stattin Norinder till nya styrelseledam\u00f6ter, om bemyndiganden f\u00f6r styrelsen att besluta om f\u00f6retr\u00e4desemission respektive riktad emission, samt att inr\u00e4tta ett teckningsoptionsbaserat incitamentsprogram f\u00f6r anst\u00e4llda. Totalt tecknades d\u00e4refter 380 000 teckningsoptioner, motsvarande en maximal utsp\u00e4dning om 1,5%.<\/li>\n<li>Nanexa l\u00e4mnande i maj 2021 in en st\u00e4mningsans\u00f6kan om patentintr\u00e5ng till en federal domstol i Delaware, USA, mot\u00a0Vitrivax, Inc.<\/li>\n<li>Nanexa beslutade i juni 2021 med st\u00f6d av bemyndigande fr\u00e5n \u00e5rsst\u00e4mman den 24 maj att genomf\u00f6ra en fullt garanterad f\u00f6retr\u00e4desemission om ca 127 miljoner kronor. Teckningsperioden l\u00f6pte fr o m den 17 juni t o m den 1 juli 2021.<\/li>\n<li>Nanexa erh\u00f6ll i juni 2021 godk\u00e4nnande i Sydkorea f\u00f6r sitt grundpatent avseende PharmaShell\u00ae-belagda l\u00e4kemedel.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Europeiska patentverket (EPO) kommunicerade avsikten att bevilja ett europeiskt patent avseende Nanexas PharmaShell\u00ae-teknologi.<\/li>\n<li>F\u00f6retr\u00e4desemissionen om 127 miljoner kronor som beslutades i juni slutf\u00f6rdes och registrerades under juli 2021.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 april \u2013 30 juni 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 342 (97) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -8 296 (-6 430) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -8 339 (-6 494) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,33 (-0,31) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -6 253 (-9 961) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 28 596 (34 089) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 30 juni 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 878 (1 289) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -14 919 (-9 899) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -15 008 (-10 020) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,64 (-0,54) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 15 905 (22 711) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 28 596 (34 089) kSEK<\/li>\n<\/ul>\n<p><em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><br \/>\u00a0 \u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a target=\"_blank\" href=\"http:\/\/www.nanexa.com\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2021-08-20 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a target=\"_blank\" class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/6e33fec4-866d-477f-a58b-0df16f42fa8d\/nanexa-delarsrapport-jan-jun-2021.pdf\" rel=\"nofollow noopener\">Nanexa Del\u00e5rsrapport Jan Jun 2021<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f6rsta kliniska studien startad och l\u00e5ngsiktig finansiering s\u00e4krad<\/p>\n","protected":false},"template":"","class_list":["post-4577","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q2_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"F\u00f6rsta kliniska studien startad och l\u00e5ngsiktig finansiering s\u00e4krad\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-08-20T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB","og_description":"F\u00f6rsta kliniska studien startad och l\u00e5ngsiktig finansiering s\u00e4krad","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-08-20T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2021"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}